西妥昔单抗
化学
表皮生长因子受体
药物输送
SKBR3型
癌细胞
纳米医学
紫杉醇
靶向给药
单克隆抗体
癌症研究
流式细胞术
靶向治疗
纳米颗粒
癌症
分子生物学
纳米技术
抗体
材料科学
生物化学
医学
受体
免疫学
生物
人体乳房
有机化学
内科学
作者
S. Maya,Lekshmi G. Kumar,Bruno Sarmento,N. Sanoj Rejinold,Deepthy Menon,Shantikumar V. Nair,Rangasamy Jayakumar
标识
DOI:10.1016/j.carbpol.2012.12.032
摘要
Nanoparticle mediated delivery of antineoplastic agents, functionalized with monoclonal antibodies has achieved extraordinary potential in cancer therapy. The objective of this study was to develop a drug delivery system comprising O-carboxymethyl chitosan (O-CMC) nanoparticles, surface-conjugated with Cetuximab (Cet) for targeted delivery of paclitaxel (PTXL) to Epidermal Growth Factor Receptor (EGFR) over-expressing cancer cells. Nanoparticles around 180±35nm and negatively charged were prepared through simple ionic gelation technique. The alamar blue assay indicated that these targeted nanoparticles displayed a superior anticancer activity compared to non-targeted nanoparticles. The nanoformulation triggered enhanced cell death (confirmed by flow cytometry) due to its higher cellular uptake. The selective uptake of Cet-PTXL-O-CMC nanoparticles by EGFR +VE cancer cells (A549, A431 and SKBR3) compared to EGFR -VE MIAPaCa-2 cells confirms the active targeting and delivery of PTXL via the targeted nanomedicine. Cet-PTXL-O-CMC nanoparticles can be used a promising candidate for the targeted therapy of EGFR over expressing cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI